A 36-year-old woman with schizoaffective disorder has been maintained on risperidone long-acting injection 37.5mg fortnightly for 3 years. She now presents with amenorrhea for 8 months and galactorrhea. Blood tests show: prolactin 3200 mIU/L (normal <500), TSH 2.1 mU/L, free T4 14 pmol/L. MRI pituitary is normal. She wishes to continue her current antipsychotic as her mental state has been stable. What is the most appropriate management strategy?
Q132
A 54-year-old man with bipolar affective disorder has been stable on lithium carbonate for 8 years. He presents to his GP with a 3-month history of increased urinary frequency and thirst, passing up to 6 liters of dilute urine daily. Blood tests show: sodium 148 mmol/L, potassium 4.1 mmol/L, urea 7.2 mmol/L, creatinine 98 μmol/L, lithium level 0.7 mmol/L. Urine osmolality is 150 mOsm/kg. What is the most likely diagnosis?
Q133
A 26-year-old man diagnosed with schizophrenia 8 months ago has been treated with olanzapine 15mg daily. He attends for review reporting that although his hallucinations have resolved, he feels emotionally flat, has no motivation, and spends most days in bed. His family confirm he rarely engages in conversation and shows little interest in activities. Mental state examination reveals blunted affect, poverty of speech, and lack of goal-directed behavior. What is the most appropriate next step in management?
Q134
A 31-year-old woman with bipolar affective disorder type I is planning pregnancy and attends for preconception counseling. She has had three previous manic episodes requiring hospitalization, the last being 18 months ago. She is currently stable on lithium 900mg daily with therapeutic levels. She has tried valproate and carbamazepine previously, both ineffective. What is the most appropriate management recommendation?
Q135
A 23-year-old man is assessed in the early intervention in psychosis service following his first psychotic episode 4 months ago. He was started on risperidone 4mg daily with good response. His family ask about his prognosis. Which factor in his presentation is associated with the most favorable long-term outcome in schizophrenia?
Q136
A 48-year-old woman with a 20-year history of schizophrenia presents to the community mental health team with involuntary movements of her mouth and tongue. She has been maintained on fluphenazine decanoate depot injection for 15 years with good symptom control. On examination, she has repetitive chewing movements and occasional tongue protrusion. These movements persist during distraction and worsen with stress. She is otherwise well with stable mental state. What is the most appropriate initial management?
Q137
A 33-year-old man with schizophrenia presents to his GP with a 4-month history of amenorrhea and galactorrhea. He takes risperidone 6mg daily prescribed by the mental health team. His psychotic symptoms are well controlled. Examination confirms bilateral galactorrhea and gynaecomastia. He is distressed by these symptoms and considering stopping his medication. Blood tests show prolactin 4200 mU/L. MRI pituitary is normal. The mental health team states he has previously relapsed on quetiapine and olanzapine. What underlying mechanism best explains his symptoms?
Q138
A 43-year-old woman with a 15-year history of schizophrenia has been on clozapine 600mg daily for 5 years with excellent symptom control. She smokes 20 cigarettes daily. She is admitted to a general medical ward for elective cholecystectomy. Post-operatively, she is not permitted to smoke due to oxygen therapy. On day 2 post-operation, she becomes increasingly drowsy and confused. Observations: BP 100/65 mmHg, HR 118 bpm, temperature 37.8°C. What is the most likely explanation for her deterioration?
Q139
A 39-year-old man with bipolar affective disorder is admitted with acute mania. He is extremely agitated, physically aggressive to staff, has not slept for 3 days, and is refusing all oral medication. He has grandiose delusions about being a prophet. Physical examination shows no signs of head injury. Vital signs: BP 145/92 mmHg, HR 110 bpm, temperature 37.2°C. He requires immediate pharmacological intervention for rapid tranquillisation. What is the most appropriate first-line medication combination?
Q140
A 27-year-old man with paranoid schizophrenia diagnosed 3 years ago presents with worsening symptoms despite medication. Review of his medication history shows: risperidone 6mg daily for 8 weeks (discontinued due to hyperprolactinaemia), then olanzapine 20mg daily for 10 weeks (discontinued due to 12kg weight gain), then aripiprazole 30mg daily for 6 weeks (ongoing). His care coordinator reports good adherence confirmed by witnessed medication. He continues to experience persecutory delusions and auditory hallucinations affecting his functioning. What is the most appropriate next step?
Severe Mental Illness UK Medical PG Practice Questions and MCQs
Question 131: A 36-year-old woman with schizoaffective disorder has been maintained on risperidone long-acting injection 37.5mg fortnightly for 3 years. She now presents with amenorrhea for 8 months and galactorrhea. Blood tests show: prolactin 3200 mIU/L (normal <500), TSH 2.1 mU/L, free T4 14 pmol/L. MRI pituitary is normal. She wishes to continue her current antipsychotic as her mental state has been stable. What is the most appropriate management strategy?
A. Add cabergoline to reduce prolactin levels
B. Switch to quetiapine
C. Reduce risperidone depot dose by 50%
D. Switch to paliperidone long-acting injection
E. Add aripiprazole to current depot (Correct Answer)
Explanation: ***Add aripiprazole to current depot***- **Aripiprazole** is a **partial dopamine agonist** that has a higher affinity for D2 receptors than risperidone, effectively lowering **prolactin** levels by providing some dopaminergic activity in the tuberoinfundibular pathway.- This strategy is ideal when a patient is clinically stable on their current regimen, as it avoids the **risk of relapse** associated with switching or reducing the primary antipsychotic.*Add cabergoline to reduce prolactin levels*- **Cabergoline** is a potent dopamine agonist typically used for prolactinomas but is generally avoided in patients with **schizoaffective disorder** or schizophrenia due to the risk of **exacerbating psychosis**.- While it lowers prolactin effectively, the potential for **psychiatric destabilization** makes it a second-line option compared to aripiprazole augmentation.*Switch to quetiapine*- **Quetiapine** is a "prolactin-sparing" antipsychotic, but switching carries a high **risk of relapse** for a patient who has been stable for three years on a specific regimen.- Transitioning from a **long-acting injection (LAI)** to an oral medication like quetiapine also increases the risk of **treatment non-adherence**.*Reduce risperidone depot dose by 50%*- Reducing the dose may lower prolactin levels, but it significantly increases the **vulnerability to relapse** of psychotic or mood symptoms.- There is no guarantee that a lower dose will resolve the **galactorrhea and amenorrhea**, especially given the patient's significantly elevated prolactin level.*Switch to paliperidone long-acting injection*- **Paliperidone** is the active metabolite of risperidone and shares the same high risk for **hyperprolactinemia** due to its potent D2 antagonism.- This switch would likely be ineffective in resolving the patient's symptoms as both medications have the same **pharmacodynamic profile** regarding prolactin elevation.
Question 132: A 54-year-old man with bipolar affective disorder has been stable on lithium carbonate for 8 years. He presents to his GP with a 3-month history of increased urinary frequency and thirst, passing up to 6 liters of dilute urine daily. Blood tests show: sodium 148 mmol/L, potassium 4.1 mmol/L, urea 7.2 mmol/L, creatinine 98 μmol/L, lithium level 0.7 mmol/L. Urine osmolality is 150 mOsm/kg. What is the most likely diagnosis?
A. Diabetes mellitus
B. Chronic kidney disease
C. Lithium toxicity
D. Nephrogenic diabetes insipidus (Correct Answer)
E. Primary polydipsia
Explanation: ***Nephrogenic diabetes insipidus***- Long-term **lithium therapy** is a classic cause of **nephrogenic diabetes insipidus** because lithium inhibits the action of **antidiuretic hormone (ADH)** on the collecting ducts, preventing water reabsorption.- The patient's **polyuria** (6 liters), **thirst**, **hypernatremia** (148 mmol/L), and **low urine osmolality** (150 mOsm/kg) demonstrate an inability to concentrate urine despite high serum concentration.*Diabetes mellitus*- While diabetes mellitus presents with **polyuria and polydipsia**, it is characterized by **osmotic diuresis** due to high glucose levels.- This patient's presentation lacks mention of **hyperglycemia or glycosuria**, and the urine is explicitly **dilute** rather than concentrated with glucose.*Chronic kidney disease*- Lithium can cause **chronic interstitial nephritis**, but this typically presents with a significant rise in **creatinine** and loss of GFR.- This patient's **creatinine (98 μmol/L)** is within the normal range, making advanced **chronic kidney disease** less likely than a specific tubular defect.*Lithium toxicity*- This patient’s **lithium level is 0.7 mmol/L**, which is within the standard **therapeutic range** (0.4–1.0 mmol/L).- **Acute toxicity** usually presents with neurological symptoms like **ataxia, coarse tremor, and confusion**, rather than isolated chronic polyuria.*Primary polydipsia*- In **primary polydipsia**, the excessive water intake leads to **hyponatremia** or low-normal sodium as the body tries to excrete the excess fluid.- This patient has **hypernatremia** (sodium 148 mmol/L), which indicates a primary **water loss** problem rather than excessive water intake.
Question 133: A 26-year-old man diagnosed with schizophrenia 8 months ago has been treated with olanzapine 15mg daily. He attends for review reporting that although his hallucinations have resolved, he feels emotionally flat, has no motivation, and spends most days in bed. His family confirm he rarely engages in conversation and shows little interest in activities. Mental state examination reveals blunted affect, poverty of speech, and lack of goal-directed behavior. What is the most appropriate next step in management?
A. Increase olanzapine to 20mg daily
B. Add an SSRI for comorbid depression
C. Switch to amisulpride
D. Add cognitive behavioral therapy for psychosis
E. Switch to aripiprazole (Correct Answer)
Explanation: ***Switch to aripiprazole***- This patient is presenting with prominent **negative symptoms** (avolition, blunted affect, poverty of speech) which may be primary or secondary to the sedating effects of **Olanzapine**.- **Aripiprazole** is a **partial dopamine agonist** that has shown benefit in improving negative symptoms and lacks the heavy sedative profile of olanzapine.*Increase olanzapine to 20mg daily*- Increasing the dose of a **second-generation antipsychotic** is unlikely to help negative symptoms and may actually worsen **secondary negative symptoms** by increasing sedation.- Since the patient’s **hallucinations** (positive symptoms) have already resolved, dose escalation is not clinically indicated.*Add an SSRI for comorbid depression*- While the symptoms overlap with depression, the clinical picture of **blunted affect** and **poverty of speech** specifically points toward the **negative symptom cluster** of schizophrenia.- **SSRIs** are generally not the first-line intervention for primary negative symptoms unless a clear **comorbid major depressive disorder** is diagnosed.*Switch to amisulpride*- While **low-dose Amisulpride** is sometimes used for negative symptoms, **Aripiprazole** is often preferred in clinical guidelines when transitioning from a more sedating agent.- Amisulpride can also lead to **hyperprolactinemia**, which is less likely to occur with a partial agonist like aripiprazole.*Add cognitive behavioral therapy for psychosis*- **CBTp** is an important adjunct for managing **residual positive symptoms** and improving social functioning, but it is not the primary immediate step for medication-induced or primary negative symptoms.- **Pharmacological optimization** should be prioritized to reduce the side-effect burden (like sedation) before assessing the full impact of psychotherapeutic interventions.
Question 134: A 31-year-old woman with bipolar affective disorder type I is planning pregnancy and attends for preconception counseling. She has had three previous manic episodes requiring hospitalization, the last being 18 months ago. She is currently stable on lithium 900mg daily with therapeutic levels. She has tried valproate and carbamazepine previously, both ineffective. What is the most appropriate management recommendation?
A. Continue lithium throughout pregnancy with close monitoring (Correct Answer)
B. Stop lithium immediately and remain medication-free
C. Switch to lamotrigine before attempting conception
D. Switch to olanzapine before attempting conception
E. Continue lithium but stop in first trimester only
Explanation: ***Continue lithium throughout pregnancy with close monitoring***- In patients with **severe bipolar I disorder** and a history of multiple hospitalizations, the high risk of **relapse** (up to 70%) often outweighs the small absolute risk of **Ebstein’s anomaly** (0.05-0.1%).- Close monitoring is essential, including **fetal echocardiography** at 18-20 weeks and frequent **serum level checks** due to changes in glomerular filtration rate during pregnancy and delivery.*Stop lithium immediately and remain medication-free*- Abruptly stopping medication in a patient with a history of manic episodes carries a massive risk of **relapse**, which can lead to severe maternal and fetal complications.- NICE guidelines advise against being medication-free in cases where the **severity of the illness** poses a significant threat to the mother's safety.*Switch to lamotrigine before attempting conception*- **Lamotrigine** is primarily effective for preventing **bipolar depression** rather than prophylaxis against the manic episodes this patient frequently experiences.- There is no evidence it would be effective for this specific patient, especially given her history of failing multiple other **mood stabilizers**.*Switch to olanzapine before attempting conception*- While **atypical antipsychotics** are an alternative, this patient is currently stable on **lithium** after failing other first-line treatments like valproate and carbamazepine.- Switching a stable patient with high-risk disease to a new agent during the preconception period risks destabilization before the pregnancy even begins.*Continue lithium but stop in first trimester only*- Stopping lithium during the **first trimester** significantly increases the risk of a relapse during and immediately after the pregnancy.- Recent evidence suggests the risk of **teratogenicity** is lower than previously feared, making continuous treatment safer than a high-risk mid-pregnancy relapse.
Question 135: A 23-year-old man is assessed in the early intervention in psychosis service following his first psychotic episode 4 months ago. He was started on risperidone 4mg daily with good response. His family ask about his prognosis. Which factor in his presentation is associated with the most favorable long-term outcome in schizophrenia?
A. Gradual onset of symptoms over 18 months
B. Prominent negative symptoms at presentation
C. Acute onset with clear precipitating stressor (Correct Answer)
D. Family history of schizophrenia in father
E. Poor premorbid social functioning
Explanation: ***Acute onset with clear precipitating stressor***
- An **acute onset** of psychosis (typically within a month) suggests a more **reactive process** to a stressor rather than a more severe underlying neurodevelopmental deficit.
- This is often associated with better **antipsychotic treatment response** and a higher likelihood of achieving full remission and better long-term functional recovery.
*Gradual onset of symptoms over 18 months*
- A **gradual or insidious onset** is consistently linked with a **poorer prognosis** in schizophrenia, as it often reflects a more progressive neurodevelopmental course.
- It typically leads to a longer duration of **untreated psychosis** before intervention, which is itself a factor associated with worse outcomes.
*Prominent negative symptoms at presentation*
- **Prominent negative symptoms** (e.g., alogia, anhedonia, avolition, flattened affect) are generally considered **poor prognostic indicators** because they are often more resistant to pharmacotherapy.
- They contribute significantly to **functional impairment** and can persist even when positive symptoms are controlled, leading to poorer long-term quality of life and social integration.
*Family history of schizophrenia in father*
- A **positive family history** of schizophrenia, especially in a first-degree relative, indicates a **stronger genetic predisposition** to the illness.
- This genetic burden is generally associated with a **less favorable prognosis**, potentially indicating a more severe or chronic disease course.
*Poor premorbid social functioning*
- **Poor premorbid social functioning** (e.g., social isolation, academic difficulties) before the onset of psychosis is a significant predictor of **poorer long-term outcomes**.
- It suggests a lack of robust social and coping skills, making it harder for individuals to recover and reintegrate into society after the psychotic episode.
Question 136: A 48-year-old woman with a 20-year history of schizophrenia presents to the community mental health team with involuntary movements of her mouth and tongue. She has been maintained on fluphenazine decanoate depot injection for 15 years with good symptom control. On examination, she has repetitive chewing movements and occasional tongue protrusion. These movements persist during distraction and worsen with stress. She is otherwise well with stable mental state. What is the most appropriate initial management?
A. Switch to clozapine immediately
B. Add tetrabenazine to current antipsychotic
C. Stop fluphenazine and observe
D. Switch to aripiprazole and monitor closely (Correct Answer)
E. Continue fluphenazine and reassure patient
Explanation: ***Switch to aripiprazole and monitor closely***
- This patient presents with **tardive dyskinesia** (TD) due to long-term use of a first-generation depot antipsychotic; switching to a second-generation antipsychotic like **aripiprazole** is a recommended initial step.
- Aripiprazole's **partial dopamine agonism** may help reduce the severity of involuntary movements while maintaining psychiatric stability.
*Switch to clozapine immediately*
- While **clozapine** has the lowest risk of worsening TD and can be therapeutic for it, it is usually reserved for **treatment-resistant schizophrenia** or severe TD cases after other trials.
- It is not the "immediate" first step due to the requirement for intensive **hematological monitoring** and a risk profile (e.g., agranulocytosis) that requires titration.
*Add tetrabenazine to current antipsychotic*
- **Tetrabenazine** is a VMAT2 inhibitor used for severe or disabling TD, but it is typically introduced after attempting to **lower the dose** or switch the primary antipsychotic.
- Adding it while keeping the patient on **fluphenazine** does not address the underlying cause of dopamine receptor hypersensitivity.
*Stop fluphenazine and observe*
- Abrupt cessation of an antipsychotic in a patient with a 20-year history of schizophrenia carries a high risk of **psychotic relapse**.
- Furthermore, stopping the drug can cause **withdrawal dyskinesia**, where the involuntary movements temporarily worsen due to the sudden loss of dopamine blockade.
*Continue fluphenazine and reassure patient*
- Continuing a first-generation antipsychotic when TD symptoms appear is inappropriate as it can lead to the movements becoming **permanent and irreversible**.
- Reassurance alone is insufficient because TD is a **progressive neurological side effect** that requires active clinical management to prevent further deterioration.
Question 137: A 33-year-old man with schizophrenia presents to his GP with a 4-month history of amenorrhea and galactorrhea. He takes risperidone 6mg daily prescribed by the mental health team. His psychotic symptoms are well controlled. Examination confirms bilateral galactorrhea and gynaecomastia. He is distressed by these symptoms and considering stopping his medication. Blood tests show prolactin 4200 mU/L. MRI pituitary is normal. The mental health team states he has previously relapsed on quetiapine and olanzapine. What underlying mechanism best explains his symptoms?
A. Dopamine D2 receptor blockade in the tuberoinfundibular pathway (Correct Answer)
B. Serotonin 5-HT2A receptor antagonism
C. Histamine H1 receptor blockade
D. Alpha-1 adrenergic receptor blockade
E. Muscarinic M1 receptor antagonism
Explanation: ***Dopamine D2 receptor blockade in the tuberoinfundibular pathway***
- **Dopamine** normally acts as a **prolactin-inhibiting factor** via D2 receptors; blocking this pathway in the **anterior pituitary** leads to disinhibition and **hyperprolactinaemia**.
- Antipsychotics like **Risperidone** are potent D2 antagonists that commonly cause symptoms such as **galactorrhea**, **gynaecomastia**, and **amenorrhea**.
*Serotonin 5-HT2A receptor antagonism*
- This mechanism is a hallmark of **atypical antipsychotics** and helps reduce **extrapyramidal side effects** by increasing dopamine in the striatum.
- It does not directly cause prolactin elevation and is actually intended to counteract some of the negative effects of pure **D2 blockade**.
*Histamine H1 receptor blockade*
- Antagonism at this receptor is primarily associated with side effects such as **sedation** and significant **weight gain**.
- It has no functional role in the regulation of prolactin secretion or the development of **galactorrhea**.
*Alpha-1 adrenergic receptor blockade*
- Blockade of these receptors typically results in **orthostatic hypotension**, dizziness, and reflex tachycardia.
- It is not involved in the **endocrine pathways** that lead to breast tissue changes or milk production.
*Muscarinic M1 receptor antagonism*
- This leads to **anticholinergic side effects**, including dry mouth, **blurred vision**, constipation, and urinary retention.
- These effects are distinct from the hormonal disturbances seen in **tuberoinfundibular** dopamine disruption.
Question 138: A 43-year-old woman with a 15-year history of schizophrenia has been on clozapine 600mg daily for 5 years with excellent symptom control. She smokes 20 cigarettes daily. She is admitted to a general medical ward for elective cholecystectomy. Post-operatively, she is not permitted to smoke due to oxygen therapy. On day 2 post-operation, she becomes increasingly drowsy and confused. Observations: BP 100/65 mmHg, HR 118 bpm, temperature 37.8°C. What is the most likely explanation for her deterioration?
A. Post-operative sepsis
B. Clozapine toxicity due to smoking cessation (Correct Answer)
C. Neuroleptic malignant syndrome
D. Post-operative delirium
E. Pulmonary embolism
Explanation: ***Clozapine toxicity due to smoking cessation***
- Polycyclic aromatic hydrocarbons in cigarette smoke induce the **CYP1A2** enzyme; sudden cessation leads to a rapid **decrease in enzyme activity**, causing serum clozapine levels to skyrocket.
- Presentation of toxicity includes **drowsiness**, **confusion**, **tachycardia**, and hypotension, typically manifesting within **48–72 hours** of stopping smoking.
*Post-operative sepsis*
- While it can cause tachycardia and confusion, day 2 post-cholecystectomy is relatively early for a full septic picture without a localized source or **significant fever**.
- Sepsis would typically present with **hypotension** and elevated inflammatory markers, whereas this patient's symptoms align more specifically with drug-induced toxicity.
*Neuroleptic malignant syndrome*
- NMS is characterized by **lead-pipe rigidity**, extremely high fevers, and marked **creatine kinase (CK)** elevation, which are not described here.
- Although tachycardia is present, the clear history of **smoking cessation** and lack of severe hyperthermia (>38.5°C) makes clozapine toxicity more plausible.
*Post-operative delirium*
- Delirium is common in older patients, but a 43-year-old with a stable long-term medication regimen is more likely to have a **pharmacological trigger**.
- Simple delirium does not usually explain the **autonomic features** like tachycardia and hypotension as clearly as clozapine toxicity does.
*Pulmonary embolism*
- A PE would typically present with **pleuritic chest pain**, **shortness of breath**, and acute hypoxia rather than primary drowsiness and confusion.
- While tachycardia is a common sign of PE, it would not be the best explanation for the **neurological deterioration** seen in the context of enforced smoking cessation.
Question 139: A 39-year-old man with bipolar affective disorder is admitted with acute mania. He is extremely agitated, physically aggressive to staff, has not slept for 3 days, and is refusing all oral medication. He has grandiose delusions about being a prophet. Physical examination shows no signs of head injury. Vital signs: BP 145/92 mmHg, HR 110 bpm, temperature 37.2°C. He requires immediate pharmacological intervention for rapid tranquillisation. What is the most appropriate first-line medication combination?
A. Intramuscular olanzapine alone
B. Intramuscular haloperidol alone
C. Intramuscular lorazepam alone
D. Intramuscular haloperidol and intramuscular promethazine (Correct Answer)
E. Intravenous diazepam alone
Explanation: ***Intramuscular haloperidol and intramuscular promethazine***
- Per **NICE guidelines**, the combination of **IM haloperidol** (5mg) and **IM promethazine** (50mg) is a primary first-line option for **rapid tranquillisation** when oral medication is refused.
- **Promethazine** is added to provide synergistic sedation and, crucially, to reduce the risk of **extrapyramidal side effects** such as acute dystonia associated with haloperidol.
*Intramuscular olanzapine alone*
- While effective, **IM olanzapine** is not typically the very first choice in many clinical settings due to specific restrictions and monitoring requirements.
- It carries a significant risk of **hypotension** and **respiratory depression** if the patient later requires or has recently received parenteral benzodiazepines.
*Intramuscular haloperidol alone*
- Administering **haloperidol** as a monotherapy carries a significantly higher risk of inducing painful **acute dystonic reactions**.
- It often provides inadequate **sedation** for a patient in a severe state of physical aggression and sleep deprivation compared to the combination therapy.
*Intramuscular lorazepam alone*
- **IM lorazepam** is a valid first-line option but may be less effective than the haloperidol combination for a patient requiring both sedation and **antipsychotic** management of mania.
- Benchmarked against the combination, it carries a higher risk of **respiratory depression** and may lead to paradoxical disinhibition in some patients.
*Intravenous diazepam alone*
- **Intravenous (IV)** administration is generally avoided in aggressive, non-compliant patients due to the difficulty of maintaining safe access and the high risk of **respiratory arrest**.
- **Diazepam** has an unpredictable absorption profile and prolonged half-life, making it less suitable for rapid control of acute psychosis compared to intramuscular options.
Question 140: A 27-year-old man with paranoid schizophrenia diagnosed 3 years ago presents with worsening symptoms despite medication. Review of his medication history shows: risperidone 6mg daily for 8 weeks (discontinued due to hyperprolactinaemia), then olanzapine 20mg daily for 10 weeks (discontinued due to 12kg weight gain), then aripiprazole 30mg daily for 6 weeks (ongoing). His care coordinator reports good adherence confirmed by witnessed medication. He continues to experience persecutory delusions and auditory hallucinations affecting his functioning. What is the most appropriate next step?
A. Add cognitive behavioural therapy for psychosis
B. Initiate clozapine treatment (Correct Answer)
C. Increase aripiprazole to 40mg daily
D. Switch to paliperidone long-acting injection
E. Add amisulpride to aripiprazole
Explanation: ***Initiate clozapine treatment***- This patient meets the criteria for **treatment-resistant schizophrenia**, having failed adequate trials of at least **two different antipsychotics** (risperidone and olanzapine) at optimal doses and durations.- **Clozapine** is the gold-standard treatment and the only antipsychotic with proven superior efficacy for **treatment-resistant schizophrenia** as per major clinical guidelines.*Add cognitive behavioural therapy for psychosis*- While **CBTp** is a valuable adjunctive treatment for schizophrenia, it is not the primary intervention for **pharmacologically treatment-resistant psychosis**.- Psychological interventions are most effective when some degree of **symptomatic stability** has been achieved through optimal pharmacological management.*Increase aripiprazole to 40mg daily*- The maximum recommended therapeutic dose for **aripiprazole** is typically 30mg daily; increasing to 40mg is off-label and unlikely to provide additional benefit given previous failures.- The patient's history of non-response to multiple agents suggests a need for an agent with a distinct mechanism of action, specifically for **treatment resistance**, rather than simply escalating the current dose.*Switch to paliperidone long-acting injection*- **Long-acting injectable antipsychotics** are primarily indicated for improving **medication adherence**, which is not an issue here as good adherence is confirmed.- Switching to another second-generation antipsychotic without proven efficacy for treatment resistance is unlikely to be more effective and would delay appropriate treatment with clozapine.*Add amisulpride to aripiprazole*- **Antipsychotic polypharmacy** (combining two antipsychotics) is generally discouraged as a first-line strategy for treatment resistance before a trial of **clozapine monotherapy**.- This approach increases the risk of **side effects** and drug interactions without clear evidence of superior efficacy compared to clozapine for treatment-resistant cases.
